Acrux Completes Enrollment In Key Phase 2 Trial

Drug delivery company Acrux (ASX: ACR), has announced that it has successfully completed enrolment of 40 patients in the final Phase 2 trial of its unique testosterone lotion for treatment of testosterone deficiency in men. Preliminary results of the trial are expected to be available in July 2007.The trial is being conducted at 8 clinics in the USA. [click link for full article]

Read More: continued here

Filed under: Endocrinology on May 9th, 2007